Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty

被引：16

作者：

Hilal, Talal ^{[1
]}

Betcher, Jeffrey A. ^{[2
]}

Leis, Jose F. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol & Med Oncol, 5881 E Mayo Blvd, Phoenix, AZ 85054 USA

[2] Mayo Clin, Dept Pharm, Phoenix, AZ USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2018年 / 13卷 / 04期

关键词：

CLL; Ibrutinib; Idelalisib; Venetoclax; Drug costs; Pharmacoeconomics; financial toxicity; OPEN-LABEL; INITIAL THERAPY; CANCER DRUGS; IBRUTINIB; RITUXIMAB; COST; IDELALISIB; CYCLOPHOSPHAMIDE; FLUDARABINE; MULTICENTER;

D O I：

10.1007/s11899-018-0461-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Small molecule tyrosine kinase inhibitors (TKIs) and BCL2 inhibitors are oral targeted therapies that have changed the treatment approach to patients with chronic lymphocytic leukemia (CLL). The aim of this review is to summarize the relevant literature on the economic impact of oral novel therapies for the treatment of CLL and discuss the underlying factors and suggested solutions for high drug prices. The cost of therapy for CLL has increased substantially since the introduction of oral therapies. This increase in cost is caused by multiple factors including cost of drug development, alternate reimbursement patterns, lack of transparency, and lack of free market competition. Oral therapies for CLL have dramatically increased costs for both patients and payers. Some solutions to overcome this include value-based pricing, transparency, and legal action that allow Medicare to negotiate drug prices with manufacturers.

引用

页码：237 / 243

页数：7

共 41 条

[11] Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer [J].

Davidoff, Amy J. ;

Erten, Mujde ;

Shaffer, Thomas ;

Shoemaker, J. Samantha ;

Zuckerman, Ilene H. ;

Pandya, Naimish ;

Tai, Ming-Hui ;

Ke, Xuehua ;

Stuart, Bruce .

CANCER, 2013, 119 (06) :1257-1265

[12] Chlorambucil in indolent chronic lymphocytic leukemia [J].

Dighiero, G ;

Maloum, K ;

Desablens, B ;

Cazin, B ;

Navarro, M ;

Leblay, R ;

Leporrier, M ;

Jaubert, J ;

Lepeu, G ;

Dreyfus, B ;

Binet, JL ;

Travade, P ;

Turpin, FL ;

Tertian, G ;

Bichoffe, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) :1506-1514

[13] Innovation in the pharmaceutical industry: New estimates of R&D costs [J].

DiMasi, Joseph A. ;

Grabowski, Henry G. ;

Hansen, Ronald W. .

JOURNAL OF HEALTH ECONOMICS, 2016, 47 :20-33

[14] Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study [J].

Dreyling, Martin ;

Jurczak, Wojciech ;

Jerkeman, Mats ;

Silva, Rodrigo Santucci ;

Rusconi, Chiara ;

Trneny, Marek ;

Offner, Fritz ;

Caballero, Dolores ;

Joao, Cristina ;

Witzens-Harig, Mathias ;

Hess, Georg ;

Bence-Bruckler, Isabelle ;

Cho, Seok-Goo ;

Bothos, John ;

Goldberg, Jenna D. ;

Enny, Christopher ;

Traina, Shana ;

Balasubramanian, Sriram ;

Bandyopadhyay, Nibedita ;

Sun, Steven ;

Vermeulen, Jessica ;

Rizo, Aleksandra ;

Rule, Simon .

LANCET, 2016, 387 (10020) :770-778

[15] Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014 [J].

Dusetzina, Stacie B. .

JAMA ONCOLOGY, 2016, 2 (07) :960-961

[16] Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial [J].

Farooqui, Mohammed Z. H. ;

Valdez, Janet ;

Martyr, Sabrina ;

Aue, Georg ;

Saba, Nakhle ;

Niemann, Carsten U. ;

Herman, Sarah E. M. ;

Tian, Xin ;

Marti, Gerald ;

Soto, Susan ;

Hughes, Thomas E. ;

Jones, Jade ;

Lipsky, Andrew ;

Pittaluga, Stefania ;

Stetler-Stevenson, Maryalice ;

Yuan, Constance ;

Lee, Yuh Shan ;

Pedersen, Lone B. ;

Geisler, Christian H. ;

Calvo, Katherine R. ;

Arthur, Diane C. ;

Maric, Irina ;

Childs, Richard ;

Young, Neal S. ;

Wiestner, Adrian .

LANCET ONCOLOGY, 2015, 16 (02) :169-176

[17] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Boettcher, Sebastian ;

Bahlo, Jasmin ;

Schubert, Joeerg ;

Pflueger, Karl H. ;

Schott, Silke ;

Goede, Valentin ;

Isfort, Susanne ;

von Tresckow, Julia ;

Fink, Anna-Maria ;

Buehler, Andreas ;

Winkler, Dirk ;

Kreuzer, Karl-Anton ;

Staib, Peter ;

Ritgen, Matthias ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Stilgenbauer, Stephan ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3209-3216

[18]

Friedberg MW, 2017, JAMA INTERN MED, V177, P1058, DOI 10.1001/jamainternmed.2017.2142

[19] Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia [J].

Furman, Richard R. ;

Sharman, Jeff P. ;

Coutre, Steven E. ;

Cheson, Bruce D. ;

Pagel, John M. ;

Hillmen, Peter ;

Barrientos, Jacqueline C. ;

Zelenetz, Andrew D. ;

Kipps, Thomas J. ;

Flinn, Ian ;

Ghia, Paolo ;

Eradat, Herbert ;

Ervin, Thomas ;

Lamanna, Nicole ;

Coiffier, Bertrand ;

Pettitt, Andrew R. ;

Ma, Shuo ;

Stilgenbauer, Stephan ;

Cramer, Paula ;

Aiello, Maria ;

Johnson, Dave M. ;

Miller, Langdon L. ;

Li, Daniel ;

Jahn, Thomas M. ;

Dansey, Roger D. ;

Hallek, Michael ;

O'Brien, Susan M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :997-1007

[20] PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma [J].

Gopal, Ajay K. ;

Kahl, Brad S. ;

de Vos, Sven ;

Wagner-Johnston, Nina D. ;

Schuster, Stephen J. ;

Jurczak, Wojciech J. ;

Flinn, Ian W. ;

Flowers, Christopher R. ;

Martin, Peter ;

Viardot, Andreas ;

Blum, Kristie A. ;

Goy, Andre H. ;

Davies, Andrew J. ;

Zinzani, Pier Luigi ;

Dreyling, Martin ;

Johnson, Dave ;

Miller, Langdon L. ;

Holes, Leanne ;

Li, Daniel ;

Dansey, Roger D. ;

Godfrey, Wayne R. ;

Salles, Gilles A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :1008-1018

← 1 2 3 4 5 →